Clinical trials: End of Life Patients
Liver Transplantation
Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients
This study will assess the safety and efficacy of different doses of sotrastaurin when combined with tacrolimus for the prevention of acute rejection after de novo liver transplantation.
- Trial name
- NCT01128335
- Testing
- MMF(1000mg bid) + tacrolimus + standard of care medications, sotrastaurin (200mg bid) + tacrolimus + standard of care medications, sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
- Where
- 39 sites in United States, Argentina and 10 more
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Nephropathy
To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
The purpose of this study is to determine whether avosentan (SPP301) is effective in decreasing morbidity and mortality in patients with diabetic nephropathy.
- Trial name
- NCT00120328
- Testing
- SPP301
- Where
- United States
- Volunteers
- 2,364 people
- Sponsor
- Speedel Pharma Ltd.
Anesthesia
Expired Propofol in Low Back Surgery
Edmon (BBraun, Germany) is a portable, commercially available device for measurement of propofol in exhaled air. The study will aim at evaluating the sensitivity and specificity of such exhaled propofol values compared with…
- Trial name
- NCT04771702
- Testing
- Edmon
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Acute Decompensated Heart Failure
Prognostic Factors of Patients With ADHF
To explore the prognostic indicators for patients with ADHF
- Trial name
- NCT04390919
- Testing
- elevated monocyte count
- Volunteers
- 362 people
- Sponsor
- Chongqing Medical University
Cardiac Death, Hemorrhage
Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
The purpose of this study is to evaluate the efficacy and safety of 5mg maintenance dose (MD) of prasugrel in patients with acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI) with BiomatrixTM…
- Conditions
- Cardiac Death, Hemorrhage, Cerebrovascular Accident, Myocardial Infarction
- Trial name
- BEAUTY-II (NCT02446730)
- Testing
- BES (biodegradable polymer biolimus-eluting stent), Prasugel, Clopidogrel
- Where
- South Korea
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Chonnam National University Hospital
HNSCC
WGA in Platinum-refractory HNSCC Underwent Nivolumab
To choose a subgroup who could clearly benefit from Nivolumab, we are proposing a prospective observational study. Whole-genome study (WGS) analysis will be performed on archived cancer tissues from patients who were (1)…
- Trial name
- NCT03917537
- Testing
- HNSCC patients have used Nivolumab
- Where
- 2 sites in Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Delayed Graft Function
Study on Delayed Graft Function Using Paired Kidneys
The study is designed to evaluate the safety and efficacy of an intravenously administered drug in recipients of kidneys from cardiac death donors who are risk for developing delayed graft function.
- Trial name
- NCT01561599
- Testing
- BB3, Normal Saline
- Where
- 3 sites in Netherlands, Spain and 1 more
- Volunteers
- 12 people
- Sponsor
- Angion Biomedica Corp
Heart Failure
Improvement of Left Ventricular Ejection Fraction in ICD Patients Undergoing Therapy With Sacubitril/Valsartan
The study is aimed to evaluate the improvement of the left ventricular volumes and of the left ventricular ejection fraction in a population of ICD patients with heart failure and left ventricle systolic dysfunction undergoing…
- Trial name
- SAVE-ICD (NCT03935087)
- Testing
- two-dimensional echocardiogram
- Where
- 6 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliera Cardinale G. Panico
Myocardial Infarction, Death
Prognostic Impact of Organ Damage in STEMI Patients
Besides contrast-induced acute kidney injury (CI-AKI), adscititious vital organ damage such as hypoxic liver injury (HLI) may affect the survival in patients with ST-elevation myocardial infarction (STEMI).
- Conditions
- Myocardial Infarction, Death, Acute Kidney Injury, Hepatic Insufficiency
- Trial name
- NCT02800421
- Volunteers
- 668 people
- Sponsor
- Inha University Hospital
End of Life
Identification of Obstacles and Levers to the Outpatient Care of Patients in Terminal Palliative Situations
80% of patients wish to die at home. The number of deaths will increase in the coming years due to the aging population. The general practitioner (GP) is at the center of this care.
- Trial name
- PTPS (NCT07191184)
- Where
- France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Strasbourg, France
Cancer
The Effectiveness of the LCP in Improving End of Life Care for Dying Cancer Patients in Hospital.
The purpose of this study is to evaluate the effectiveness of the LCP-I Program in improving the quality of end-of-life care provided to cancer patients who die on hospital medical wards as compared to standard healthcare…
- Trial name
- NCT01081899
- Testing
- The LCP-I Program
- Where
- Italy
- Volunteers
- 308 people
- Sponsor
- Regional Palliative Care Network
Gastric Neoplasms, Gastroesophageal Adenocarcinoma
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
- Conditions
- Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- HERIZON-GEA-01 (NCT05152147)
- Testing
- Zanidatamab, Tislelizumab, Trastuzumab
- Where
- 227 sites in Argentina, Australia and 31 more
- Volunteers
- 920 people
- Sponsor
- Jazz Pharmaceuticals
End-stage Chronic Kidney Disease Treated With Hemodialysis, Depressive Disorders
Evaluation of the Effect of Light Therapy on the Evolution of Self-reported Depressive Disorders in Chronic Hemodialysis Patients
Hemodialysis is an intensive treatment, with a lifestyle dictated by the organization of the dialysis center. This treatment is associated with a decrease in quality of life, an increase in sleep disorders, and depressive…
- Trial name
- LUMIDIAL-2 (NCT07729358)
- Testing
- Light therapy using active glasses, Light therapy using inactive glasses
- Where
- France
- Volunteers
- 340 people
- Sponsor
- Centre Hospitalier Annecy Genevois
Terminal Cancer, End Stage Cancer
Using Wearable Device to Improve Quality of Palliative Care
This study is going to use wearable devices and smartphones to collect physical data from terminal patients and build a survival predicting model for terminal patients with machine learning.
- Trial name
- NCT05054907
- Where
- 2 sites in Taiwan
- Volunteers
- 75 people
- Sponsor
- National Taiwan University Hospital
Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
This is an open-label, non-randomized, Phase I study of epacadostat (INCB024360) alone and in combination with pembrolizumab with chemotherapy and pembrolizumab without chemotherapy in participants with advanced solid tumors.
- Trial name
- NCT02862457
- Testing
- Epacadostat 25 mg, Epacadostat 100 mg, pembrolizumab 200 mg
- Volunteers
- 34 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous…
- Trial name
- TRITON (NCT06008093)
- Testing
- Durvalumab, Tremelimumab, Pemetrexed
- Where
- 47 sites in United States
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Plaque, Atherosclerotic, Immune Checkpoint Inhibitors
A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
- Conditions
- Plaque, Atherosclerotic, Immune Checkpoint Inhibitors, Programmed Cell Death Protein 1 Inhibitor, Carotid Artery Plaque
- Trial name
- NCT05123287
- Testing
- PD-1 immune checkpoint blockades
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
COVID-19, Kidney Injury
Morphofunctional, Gene, Inflammation Molecules and Oxidative Stress Analysis in Kidney Tissue of COVID-19 Patients
The involvement of the kidneys in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the outset of the pandemic was associated with high mortality rates worldwide.
- Conditions
- COVID-19, Kidney Injury, Gene Amplification, Oxidative Stress
- Trial name
- NCT06444893
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
Systolic Heart Failure, Sudden Cardiac Death
A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)
The purpose of this study is to test the acceptability and feasibility of a "toolkit" of patient decision aids (PtDAs) for heart failure patients who are considering an ICD implant.
- Trial name
- NCT02026102
- Testing
- ICD Decision Aid Toolkit
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Colorado, Denver
Hematologic Malignancy, Acute Leukemia
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07710781
- Testing
- Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated
- Volunteers
- 300 people
- Sponsor
- Ossium Health, Inc.